A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

MiniMed Group, Inc. Common Stock MMED

Mixed broader-coverage candidate · MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company

On FrontierLab's discovery record since 2026-08-07 (2 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-08), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	15.6%
Gross margin	57.3%
Gross profits / assets	0.41
Rule of 40	25.4
Net margin	9.8%
Cash runway (months)	5.3
PEG	—
Price / sales	1.6

Quality checklist

~ Revenue growth — 15.6% (pass ≥ 20%)
✓ Gross profits / assets — 0.41 (pass ≥ 0.33)
~ Gross margin — 57.3% (pass ≥ 60%)
✗ Cash generation

Fundamentals — snapshot as of 2026-08-08

Stage	Established
Share issuance (YoY)	—
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-2.72
Burn multiple	0.2
Gross-margin trend (pts)	—
Cash / assets	0.06
Net debt / EBITDA	-0.5
Statements as of	Q4 FY2025 · filed 2026-06-29

Momentum context — a snapshot from 2026-08-08, not current

Price at surface	$19.60 (as of 2026-08-08)
52-week range	$10.65 – $20.48
% off 52-wk high	-4.3%
RSI (14)	72
Relative volume	1.4×

Risk flags

Cash runway ~5 months at current burn — a dilutive raise looks imminent.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-08 (end-of-day). How grades are computed →